What is the current status of the Zantac lawsuit?

The Zantac litigation is currently active with ~926 pending (851 per JPML March 2, 2026 report, plus ~75 new filings tracked) plaintiffs. Filing trend: Federal inventory collapsed post-settlement; GSK resolved ~80,000 state claims, Pfizer ~10,000, Sanofi ~4,000.

Has there been a Zantac settlement?

GSK up-to-$2.2B settlement (Oct 2024) resolving ~93% of its U.S. state-court claims (~80,000 plaintiffs) in disbursement phase; Pfizer ~10,000 cases settled; Sanofi ~4,000 cases settled; Boehringer Ingelheim, Pfizer, Sanofi state-court litigation continues

What verdicts have been reached in Zantac cases?

No verdicts yet in active dockets; Connecticut bellwether trials scheduled March 14, 2028 (colorectal), September 2028 (stomach), early 2029 (prostate)

What is the statute of limitations for Zantac claims?

{"entries":[{"state":"Delaware","duration":"2 years","rule":"Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)","discoveryRule":"No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design d

LexGeniusYour Edge in Mass Litigation

Pricing Daily Docket Track litigations free Sign in

Active MDL104 eventsPharmaceutical

Zantac

Q: What is the Zantac lawsuit about?

{"summary":"The Zantac litigation has shifted to state court settlements exceeding $12 billion as of July 2026, after MDL 2924 was dismissed in December 2022. Judge Robin L. Rosenberg granted summary judgment for all defendants in the federal MDL (In re: Zantac (Ranitidine) Products Liability Litigation, 644 F.Supp.3d 1075 (S.D. Fla. 2022)), excluding plaintiffs' general causation experts under Da

Pharmaceutical · claims concerning NDMA contamination and alleged cancer risk from ranitidine products

Defendant

GlaxoSmithKline LLC

MDL / Track

MDL 2924

S.D. Fla.

Judge

Judge Robin L. Rosenberg

Plaintiffs

~926 pending (851 per JPML March 2, 2026 report, plus ~75 new filings tracked)

Bellwether / Trial

No verdicts yet in active dockets
Connecticut bellwether trials scheduled March 14, 2028 (colorectal), September 2028 (stomach), early 2029 (prostate)

Settlement Status

GSK up-to-$2.2B settlement (Oct 2024) resolving ~93% of its U.S. state-court claims (~80,000 plaintiffs) in disbursement phase
Pfizer ~10,000 cases settled
Sanofi ~4,000 cases settled
Boehringer Ingelheim, Pfizer, Sanofi state-court litigation continues

SharePost on X Share on Bluesky Share on LinkedIn Share on Facebook Email

Track litigations for free. Save this matter, capture notes, and monitor live signals.

← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity Leadership News PubMed openFDA Court filings

Case overview

The Zantac litigation has shifted to state court settlements exceeding $12 billion as of July 2026, after MDL 2924 was dismissed in December 2022. Judge Robin L. Rosenberg granted summary judgment for all defendants in the federal MDL (In re: Zantac (Ranitidine) Products Liability Litigation, 644 F.Supp.3d 1075 (S.D. Fla. 2022)), excluding plaintiffs' general causation experts under Daubert; the ruling is on appeal to the Eleventh Circuit. Sanofi, GlaxoSmithKline, and Pfizer have reached large-scale settlements covering tens of thousands of state court claims, while Boehringer Ingelheim and some generic manufacturers continue active litigation in Delaware and other state courts.

Causation Theory

Plaintiffs' theory holds that ranitidine's molecular structure is inherently unstable, degrading into N-nitrosodimethylamine (NDMA) during normal storage and distribution, with heat accelerating the conversion. NDMA is classified as a probable human carcinogen by the EPA and IARC. The FDA withdrew all ranitidine products in April 2020 after testing confirmed some samples exceeded the agency's 96 nanogram daily intake limit.

Case Management Orders

Litigation status

The federal MDL-2924 remains stayed pending the Eleventh Circuit's review of Judge Robin L. Rosenberg's December 2022 Daubert dismissal; oral arguments were held October 10, 2025, with decision pending. State-court litigation dominates: Delaware Superior Court dismissed 80,000+ cases on April 14, 2026 (C.A. No. N22C-09-101 ZAN) following the Delaware Supreme Court's July 10, 2025 reversal of Judge Vivian Medinilla's pro-plaintiff evidentiary ruling; Connecticut bellwether trials are scheduled for March 2028.

MDL Track

MDL 2924

S.D. Fla.

Zantac (ranitidine) products liability

851 pending

State Court Activity

Delaware: 80,000+ dismissed April 2026; Connecticut: bellwether trials scheduled 2028-2029; California: coordinated proceedings active in San Francisco Superior Court; Illinois: trials anticipated 2026; Pennsylvania and New Jersey: cases pending

MDL 2924 Leadership

Plaintiff Leadership

Co-Lead Counsel

Michael L. McGlamry

Pope McGlamry, P.C.

mmcglamry@popemcglamry.com (404) 523-7706

Bobby Gilbert

Kopelowitz Ostrow Ferguson Weiselberg Gilbert

bgilbert@kofglaw.com (305) 229-8333

Tracy A. Finken Magnotta

Anapol Weiss

tfinken@anapolweiss.com (215) 735-0773

Adam Pulaski

Pulaski Kherkher, PLLC

apulaski@pulaskilawfirm.com (713) 664-4555

Defense Leadership

Co-Lead Counsel

Joseph G. Petrosinelli

Williams & Connolly LLP

jpetrosinelli@wc.com (202) 434-5000

Geographic exposure

Approximately 150,000 potential claimants registered in Census Registry per MDL filings. FDA April 2020 market withdrawal treated as discovery rule trigger; SOL windows closing rapidly in 1-2 year jurisdictions. Federal MDL 2924 (S.D. Fla.) effectively paused pending Eleventh Circuit appeal.

Delaware
Over 80,000 claims dismissed in April 2026 mass dismissal — largest single-state claim volume in Zantac litigation.
Connecticut
Bellwether trials scheduled beginning 2028. Active state court litigation continues while federal MDL remains paused.
California
Multiple state court trials resulted in defense verdicts.
Illinois
Multiple state court trials resulted in defense verdicts.
Florida
Federal MDL 2924 pending before Judge Robin L. Rosenberg in S.D. Fla. State courts issued rulings on expert testimony admissibility. Census Registry captured tens of thousands of unfiled claims per DE 547.
Puerto Rico
Named jurisdiction in Master Complaints. Claims pursued under territorial law alongside 50-state consolidated litigation.
District of Columbia
Named jurisdiction in Master Complaints. CCCAC plaintiffs include D.C. residents.

Key defendants

GlaxoSmithKline LLC

Role: Brand Manufacturer

Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024.

Boehringer Ingelheim Pharmaceuticals, Inc.

Role: Brand Manufacturer

Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard.

Sanofi US Services Inc.

Role: Brand Manufacturer

Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order.

Pfizer Inc.

Role: Brand Manufacturer

Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims.

Patheon Manufacturing Services, LLC

Role: Contract Manufacturer

CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories.

Defendant	Role	Intelligence Note
GlaxoSmithKline LLC	Brand Manufacturer	Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024.
Boehringer Ingelheim Pharmaceuticals, Inc.	Brand Manufacturer	Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard.
Sanofi US Services Inc.	Brand Manufacturer	Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order.
Pfizer Inc.	Brand Manufacturer	Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims.
Patheon Manufacturing Services, LLC	Contract Manufacturer	CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories.

Timeline

2026-07
Delaware Supreme Court Reverses Expert Admissibility
Delaware Supreme Court reverses Superior Court Judge Vivian L. Medinilla's May 2024 ruling, holding trial court applied wrong Daubert standard for plaintiffs' general causation experts; remands for stricter evaluation tying opinions to ranitidine itself.
2026-04
Delaware Judge Dismisses 80,000 Boehringer Cases
Delaware Superior Court dismisses over 80,000 pre-December 2025 Zantac lawsuits against Boehringer Ingelheim following Delaware Supreme Court's stricter Daubert mandate; general causation testimony excluded.
2026-06
Federal MDL-2924 Case Count Collapses to 847
Pending cases in In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924 (S.D. Fla.) fall to roughly 847 after mass settlements by Pfizer (~10,000 cases) and Sanofi (~4,000 cases); GSK settlement closed to new claimants.
2025-10
Pfizer Settles Connecticut State-Court Cases
Pfizer reaches confidential settlements in two Connecticut state-court Zantac cases covering 17 plaintiffs total, filed in Waterbury; employs 'innovator liability' theory.
2024-10
GSK Announces $2.2 Billion Settlement
GlaxoSmithKline confirms agreements to resolve approximately 93% of its U.S. state-court Zantac cases—roughly 80,000 plaintiffs—for up to $2.2 billion; no admission of liability. Disbursement begins 2026 via claims administrator BrownGreer LLC.
2022-12
Federal MDL Daubert Dismissal
Judge Robin L. Rosenberg issues 341-page ruling in In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924 (S.D. Fla.), excluding all ten plaintiffs' general causation experts under Daubert; grants summary judgment for defendants on five designated cancers. Ruling pending 11th Circuit appeal as of 2026.
2020-02
MDL-2924 Consolidated
U.S. Judicial Panel on Multidistrict Litigation creates In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, transferring federal cases to Southern District of Florida before Judge Robin L. Rosenberg.
2020-04
FDA Requests Market Withdrawal
FDA requests voluntary withdrawal of all prescription and over-the-counter ranitidine products from U.S. market after determining NDMA levels increase over time, particularly at higher temperatures.
2019-09
Valisure Files FDA Citizen Petition
Connecticut testing laboratory Valisure LLC files citizen petition reporting detection of NDMA levels in ranitidine exceeding FDA acceptable daily intake limits; triggers recall cascade and litigation.

Statute of limitations

MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) was created February 6, 2020; Daubert ruling excluded plaintiffs' general causation experts December 2022, triggering remand of remaining cases. No MDL-wide tolling order currently in effect. FDA requested market withdrawal of all ranitidine products April 1, 2020 due to NDMA contamination risk. State SOL accrual dates vary by jurisdiction; April 2020 FDA action serves as reference date for discovery-rule analysis in most states.

Delaware

2 years

Rule: Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)

Discovery: No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025

Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order

State	SOL	Rule	Discovery Rule	Notes
Delaware	2 years	Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)	No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025	Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order

Live intelligence

AI litigation brief

Zantac remains active mdl with 104 current signals in the accepted feed.

Overview

Key developments

PACER court filing on Dec 31: Zantac (Ranitidine) Products Liability Litigation
Law.com news on Jul 23: Judge Blasts Firm Trying to Kick Him Off Phila. Zantac Litigation - Law.com
OpenFDA recall on Jun 24: FDA Recall: Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle,
PubMed research on Aug 4: Sex and base excision repair as key susceptibility factors for alkylation-induced mutations, toxicity and hepatic cancer.

Trajectory

Court filings and press coverage are both active in MDL 2924, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.

Editorial intelligence

MDL 2924 should stay on the lead docket watch because it is the primary consolidation vehicle for Zantac.

Generated Aug 12, 2026, 2:00 AM UTC

104 events detected

Google News (10)

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Sex and base excision repair as key susceptibility factors for alkylation-induced mutations, toxicity and hepatic cancer.

DNA repair • Engelward BP • PMID 42566817 • Journal Article.

Confidence 74%Published Aug 4, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Electrochemical Formation of N-Nitrosodimethylamine in Nitrite-Impacted Waters.

Environmental science & technology • Plata DL • PMID 42484880 • Journal Article.

Confidence 74%Published Aug 4, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Fluorescent Detection of Aqueous N-Nitrosodimethylamine via Photochemical Transformation and Affinity Capture.

Journal of the American Chemical Society • Swager TM • PMID 42425525 • Journal Article.

Confidence 74%Published Jul 9, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

The medical impact of emergent banning of N-nitrosodimethylamine: contaminated antihypertensive drug.

The Korean journal of internal medicine • Lee HY • PMID 42438908 • Journal Article.

Confidence 74%Published Jul 1, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Capillary flow-driven paper-based microfluidic sensor for NDMA detection in water.

Lab on a chip • Henry CS • PMID 42205061 • Journal Article.

Confidence 74%Published Jul 1, 2026, 12:00 AM UTCSource →

PACERJPMLmdl-2924-stubDec 31, 2099, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket filed in JPML: The plaintiffs are suing GlaxoSmithKline LLC, alleging that the medication Zantac (ranitidine) caused them to develop cancer. This lawsuit is part of a larger Multidistrict Litigation (MDL) where it is claimed that Zantac leads to cancer due to NDMA, a compound formed from the medication. The legal

PACERPAED2:26-cv-05662Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527999.), filed by WESLEY HOUSE. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05660Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527936.), filed by STEVEN DANKS. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05659Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527901.), filed by SHERRY TAYLOR. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05657Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527865.), filed by SALOMON RAMOS. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05656Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527813.), filed by PAMELA HILSCHER. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05655Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527773.), filed by MARK JONES. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05654Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527707.), filed by LINDA LIPKEY. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05650Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527641.), filed by LANDON KRUEGER. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

PACERPAED2:26-cv-05649Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19527597.), filed by GINA BONAVENTURA. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 08/07/2026)

Workbench

LexGenius Ranking

92Score

Court, news, and regulatory activity are elevated

Evidence20 / 20

Momentum20 / 20

Exposure16 / 20

Regulatory16 / 20

Legal20 / 20

Monitoring

Live

monitoring

Last: Aug 12, 2026, 2:00 AM UTC

Next: —

Source Monitoring

PACER

1m 26s

PACER

2m 26s

Google News

1m 26s

FAERS

11m 26s

PubMed

26m 26s

Event feed

104

events detected

Google NewsPACERFAERSPubMed

AI Brief

Zantac remains active mdl with 104 current signals in the accepted feed.

Overview

Key developments

PACER court filing on Dec 31: Zantac (Ranitidine) Products Liability Litigation. ‖ Law.com news on Jul 23: Judge Blasts Firm Trying to Kick Him Off Phila. Zantac Litigation - Law.com. ‖ openFDA recall on Jun 24: FDA Recall: Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle,. ‖ PubMed research on Aug 4: Sex and base excision repair as key susceptibility factors for alkylation-induced mutations, toxicity and hepatic cancer..

Generated Aug 12, 2026, 2:00 AM UTC

Tracked MDLs

MDL 2924

S.D. Fla.

Zantac (ranitidine) products liability

← Previous

California Women's Prisons

Monitors litigation, oversight, and policy reporting involving abuse claims in California women’s prisons.

Abbott Spinal Cord Stimulators

Tracks pending JPML consolidation proceedings alleging Abbott spinal cord stimulator devices caused neurological injury, device migration, failed pain relief, and other serious complications.

Active MDL104 eventsPharmaceutical

Zantac

Pharmaceutical · claims concerning NDMA contamination and alleged cancer risk from ranitidine products

Defendant

GlaxoSmithKline LLC

MDL / Track

MDL 2924

S.D. Fla.

Judge

Judge Robin L. Rosenberg

Plaintiffs

~926 pending (851 per JPML March 2, 2026 report, plus ~75 new filings tracked)

Bellwether / Trial

No verdicts yet in active dockets
Connecticut bellwether trials scheduled March 14, 2028 (colorectal), September 2028 (stomach), early 2029 (prostate)

Settlement Status

GSK up-to-$2.2B settlement (Oct 2024) resolving ~93% of its U.S. state-court claims (~80,000 plaintiffs) in disbursement phase
Pfizer ~10,000 cases settled
Sanofi ~4,000 cases settled
Boehringer Ingelheim, Pfizer, Sanofi state-court litigation continues

SharePost on X Share on Bluesky Share on LinkedIn Share on Facebook Email

Track litigations for free. Save this matter, capture notes, and monitor live signals.

← Torts Case overview Litigation status Geographic exposure Key defendants Timeline Statute of limitations Live activity Leadership News PubMed openFDA Court filings

Case overview

Causation Theory

Case Management Orders

Litigation status

MDL Track

MDL 2924

S.D. Fla.

Zantac (ranitidine) products liability

851 pending

State Court Activity

MDL 2924 Leadership

Plaintiff Leadership

Co-Lead Counsel

Michael L. McGlamry

Pope McGlamry, P.C.

mmcglamry@popemcglamry.com (404) 523-7706

Bobby Gilbert

Kopelowitz Ostrow Ferguson Weiselberg Gilbert

bgilbert@kofglaw.com (305) 229-8333

Tracy A. Finken Magnotta

Anapol Weiss

tfinken@anapolweiss.com (215) 735-0773

Adam Pulaski

Pulaski Kherkher, PLLC

apulaski@pulaskilawfirm.com (713) 664-4555

Defense Leadership

Co-Lead Counsel

Joseph G. Petrosinelli

Williams & Connolly LLP

jpetrosinelli@wc.com (202) 434-5000

Geographic exposure

Delaware
Over 80,000 claims dismissed in April 2026 mass dismissal — largest single-state claim volume in Zantac litigation.
Connecticut
Bellwether trials scheduled beginning 2028. Active state court litigation continues while federal MDL remains paused.
California
Multiple state court trials resulted in defense verdicts.
Illinois
Multiple state court trials resulted in defense verdicts.
Florida
Federal MDL 2924 pending before Judge Robin L. Rosenberg in S.D. Fla. State courts issued rulings on expert testimony admissibility. Census Registry captured tens of thousands of unfiled claims per DE 547.
Puerto Rico
Named jurisdiction in Master Complaints. Claims pursued under territorial law alongside 50-state consolidated litigation.
District of Columbia
Named jurisdiction in Master Complaints. CCCAC plaintiffs include D.C. residents.

Key defendants

GlaxoSmithKline LLC

Role: Brand Manufacturer

Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024.

Boehringer Ingelheim Pharmaceuticals, Inc.

Role: Brand Manufacturer

Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard.

Sanofi US Services Inc.

Role: Brand Manufacturer

Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order.

Pfizer Inc.

Role: Brand Manufacturer

Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims.

Patheon Manufacturing Services, LLC

Role: Contract Manufacturer

CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories.

Defendant	Role	Intelligence Note
GlaxoSmithKline LLC	Brand Manufacturer	Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024.
Boehringer Ingelheim Pharmaceuticals, Inc.	Brand Manufacturer	Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard.
Sanofi US Services Inc.	Brand Manufacturer	Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order.
Pfizer Inc.	Brand Manufacturer	Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims.
Patheon Manufacturing Services, LLC	Contract Manufacturer	CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories.

Timeline

2026-07
Delaware Supreme Court Reverses Expert Admissibility
Delaware Supreme Court reverses Superior Court Judge Vivian L. Medinilla's May 2024 ruling, holding trial court applied wrong Daubert standard for plaintiffs' general causation experts; remands for stricter evaluation tying opinions to ranitidine itself.
2026-04
Delaware Judge Dismisses 80,000 Boehringer Cases
Delaware Superior Court dismisses over 80,000 pre-December 2025 Zantac lawsuits against Boehringer Ingelheim following Delaware Supreme Court's stricter Daubert mandate; general causation testimony excluded.
2026-06
Federal MDL-2924 Case Count Collapses to 847
Pending cases in In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924 (S.D. Fla.) fall to roughly 847 after mass settlements by Pfizer (~10,000 cases) and Sanofi (~4,000 cases); GSK settlement closed to new claimants.
2025-10
Pfizer Settles Connecticut State-Court Cases
Pfizer reaches confidential settlements in two Connecticut state-court Zantac cases covering 17 plaintiffs total, filed in Waterbury; employs 'innovator liability' theory.
2024-10
GSK Announces $2.2 Billion Settlement
GlaxoSmithKline confirms agreements to resolve approximately 93% of its U.S. state-court Zantac cases—roughly 80,000 plaintiffs—for up to $2.2 billion; no admission of liability. Disbursement begins 2026 via claims administrator BrownGreer LLC.
2022-12
Federal MDL Daubert Dismissal
Judge Robin L. Rosenberg issues 341-page ruling in In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924 (S.D. Fla.), excluding all ten plaintiffs' general causation experts under Daubert; grants summary judgment for defendants on five designated cancers. Ruling pending 11th Circuit appeal as of 2026.
2020-02
MDL-2924 Consolidated
U.S. Judicial Panel on Multidistrict Litigation creates In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, transferring federal cases to Southern District of Florida before Judge Robin L. Rosenberg.
2020-04
FDA Requests Market Withdrawal
FDA requests voluntary withdrawal of all prescription and over-the-counter ranitidine products from U.S. market after determining NDMA levels increase over time, particularly at higher temperatures.
2019-09
Valisure Files FDA Citizen Petition
Connecticut testing laboratory Valisure LLC files citizen petition reporting detection of NDMA levels in ranitidine exceeding FDA acceptable daily intake limits; triggers recall cascade and litigation.

Statute of limitations

Delaware

2 years

Rule: Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)

Discovery: No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025

Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order

State	SOL	Rule	Discovery Rule	Notes
Delaware	2 years	Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)	No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025	Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order

Live intelligence

AI litigation brief

Zantac remains active mdl with 104 current signals in the accepted feed.

Overview

Key developments

PACER court filing on Dec 31: Zantac (Ranitidine) Products Liability Litigation
Law.com news on Jul 23: Judge Blasts Firm Trying to Kick Him Off Phila. Zantac Litigation - Law.com
OpenFDA recall on Jun 24: FDA Recall: Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle,
PubMed research on Aug 4: Sex and base excision repair as key susceptibility factors for alkylation-induced mutations, toxicity and hepatic cancer.

Trajectory

Court filings and press coverage are both active in MDL 2924, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.

Editorial intelligence

MDL 2924 should stay on the lead docket watch because it is the primary consolidation vehicle for Zantac.

Generated Aug 12, 2026, 2:00 AM UTC

104 events detected

Google News (10)

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Sex and base excision repair as key susceptibility factors for alkylation-induced mutations, toxicity and hepatic cancer.

DNA repair • Engelward BP • PMID 42566817 • Journal Article.

Confidence 74%Published Aug 4, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Electrochemical Formation of N-Nitrosodimethylamine in Nitrite-Impacted Waters.

Environmental science & technology • Plata DL • PMID 42484880 • Journal Article.

Confidence 74%Published Aug 4, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Fluorescent Detection of Aqueous N-Nitrosodimethylamine via Photochemical Transformation and Affinity Capture.

Journal of the American Chemical Society • Swager TM • PMID 42425525 • Journal Article.

Confidence 74%Published Jul 9, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

The medical impact of emergent banning of N-nitrosodimethylamine: contaminated antihypertensive drug.

The Korean journal of internal medicine • Lee HY • PMID 42438908 • Journal Article.

Confidence 74%Published Jul 1, 2026, 12:00 AM UTCSource →

StudyPubMed

Detected Aug 12, 2026, 2:19 AM UTC

Capillary flow-driven paper-based microfluidic sensor for NDMA detection in water.

Lab on a chip • Henry CS • PMID 42205061 • Journal Article.

Confidence 74%Published Jul 1, 2026, 12:00 AM UTCSource →

PACERJPMLmdl-2924-stubDec 31, 2099, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05662Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05660Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05659Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05657Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05656Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05655Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05654Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05650Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

PACERPAED2:26-cv-05649Aug 7, 2026, 12:00 AM UTC

Zantac (Ranitidine) Products Liability Litigation

Workbench

LexGenius Ranking

92Score

Court, news, and regulatory activity are elevated

Evidence20 / 20

Momentum20 / 20

Exposure16 / 20

Regulatory16 / 20

Legal20 / 20

Monitoring

Live

monitoring

Last: Aug 12, 2026, 2:00 AM UTC

Next: —

Source Monitoring

PACER

1m 26s

PACER

2m 26s

Google News

1m 26s

FAERS

11m 26s

PubMed

26m 26s

Event feed

104

events detected

Google NewsPACERFAERSPubMed

AI Brief

Zantac remains active mdl with 104 current signals in the accepted feed.

Overview

Key developments

Generated Aug 12, 2026, 2:00 AM UTC

Tracked MDLs

MDL 2924

S.D. Fla.

Zantac (ranitidine) products liability

← Previous

California Women's Prisons

Monitors litigation, oversight, and policy reporting involving abuse claims in California women’s prisons.

Abbott Spinal Cord Stimulators

Tracks pending JPML consolidation proceedings alleging Abbott spinal cord stimulator devices caused neurological injury, device migration, failed pain relief, and other serious complications.